A consortium of investors completed the acquisition of a majority stake in SEQENS from Eurazeo.

A consortium of investors including SK Capital, Bpifrance, Mérieux Equity Partners, Ardian, and Eximium, completed the acquisition of a majority stake in SEQENS, a provider of pharmaceutical ingredients and specialty chemicals, from Eurazeo, an investment company. Financial terms were not disclosed. “SEQENS is well regarded for its recognized know-how, capacity for innovation, global industrial footprint and broad portfolio of products and technologies. The potential combination with Wavelength will further extend these strengths to the benefit of both companies’ customers and employees. We are enthusiastic about the continuing commitment to SEQENS of its current shareholders, Mérieux Equity Partners, Ardian and Eximium as well as Nov Santé, which will provide the company with a broad range of perspectives and capital sources to further its growth.” Aaron Davenport, SK Capital Managing Director.